Reuters Health Report: September 4, 2015

Click to View in Browser Friday, September 4, 2015 Roche hemophilia drug wins fast-track FDA designation ZURICH (Reuters) - Roche said on Friday it had won breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental hemophilia medicine, aiming for a piece of the $11 billion hemophilia drug market. WHO sounds alarm over big Indian supplier of tuberculosis drugs LONDON/MUMBAI (Reuters) - A major Indian supplier of tuberculosis drugs to developing countries has been severely criticized by the World Health Organization for inadequate manufacturing standards and poor testing procedures. Philips aims to take healthcare from hospitals into homes BERLIN (Reuters) - Philips Electronics will emerge from its radical transition away from the lighting industry as a more profitable company focused on consumer healthcare, the head of the group's Personal Health business told Reuters. Novartis wins EU approval for multiple myeloma drug Farydak ZURICH (Reuters) - Novartis AG said on Friday it received European Union approval for Farydak, a treatment for multiple myeloma that the company said gives new options for adult patients whose disease has progressed following standard therapy. FDA delays decision on key Alexion drug by 3 months (Reuters) - Alexion Pharmaceuticals Inc said the U.S. Food and Drug Administration would delay by three months its decision on approving a key drug the company got through the acquisition of Synageva BioPharma Corp. Cosmo gets U.S. approval for agent aimed at easing polyp removal ZURICH (Reuters) - Cosmo Pharmaceuticals SA said on Friday that the U.S. Food and Drug Administration has given marketing authorization for SIC 8000, a product used in gastrointestinal tract procedures. Extra screen time drags down teenagers' exam grades, study finds LONDON (Reuters) - Teenagers who spend an extra hour a day surfing the internet, watching TV or playing computer games risk performing two grades worse in exams than their peers who don't, according to research by British scientists. AstraZeneca wins U.S. approval for longer use of blood thinner (Reuters) - U.S. regulators have approved a new dose of AstraZeneca's blood thinner Brilinta for longer-term use in patients with a history of heart attacks, boosting prospects for a drug the company thinks will eventually sell $3.5 billion a year. Chipotle critic turns up heat with 'Chubby Chipotle' ad LOS ANGELES (Reuters) - Chipotle Mexican Grill Inc, known for its indulgent burritos, is battling a "Chubby Chipotle" ad campaign from the food industry group whose "Nanny" ads helped sink New York City's ban on super-sized sugary drinks. Pentagon launches lab review, widens moratorium after anthrax find WASHINGTON (Reuters) - The Pentagon has launched a safety review at nine U.S. military labs and expanded a moratorium on the production and shipment of deadly toxins after anthrax contamination was discovered in a Utah facility. Related Video America's school buses are getting greener Snot-filled whale research takes flight A quick-fix on the day's news delivered when you want it. Register Today A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today » » MORE NEWSLETTERS - 3 Times Square New York, NY 10036 USA © Copyright 2015 Thomson Reuters Ensure delivery of Reuters Newsmails, add newsletters@email.reuters.com to your address book. Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook